1.A case report of multifocal gouty bursitis.
Hyung Ku YOON ; Kwang Pyo JEON ; Kuk Whan OH ; Dong Jun KIM ; Ki Dong JUNG
The Journal of the Korean Orthopaedic Association 1991;26(2):544-547
No abstract available.
Bursitis*
2.Availability of treatment of congenital calcaneovalgus.
Hyung Ku YOON ; Kwang Pyo JEON ; Kuk Whan OH ; Dae Eun JUNG ; Dong Jun KIM ; Han Lim KIM
The Journal of the Korean Orthopaedic Association 1992;27(7):1674-1681
No abstract available.
3.Clinical Study for Lateral Condyle Fracture of Humerus in Children
Hyung Ku YON ; Kwang Pyo JEON ; Kuk Whan OH ; Dae Eun JUNG ; Kyung Hoon KANG ; Min Su YOON
The Journal of the Korean Orthopaedic Association 1994;29(2):415-422
From January 1988 to December 1991, 39 fractures of the lateral condyle of humerus in children were treated at the Department of Orthopaedic Surgery, Sung-Ac General Hospital. It was possible to follow up from one year to four years and eleven months. The authors have analyzed the method of treatment on the basis of the degree of displacement in the change of Carrying angle and Baumann's angle. The results were as follows; 1. Of the 39 cases, the age incidence was confined to 2 to 12 years of age and the average age of the patients were 5 years. 2. Most fractures were Milch type II (29 cases) in contrast to Milch type I (10 cases). 3. According to the initial displacement of the fracture, 8 cases were Jokob's stage I, 21 cases of stage II & 10 cases of stage III. 4. There were no significant difference in the range of change of Carrying angle and Baumann's angle according to initial displacement of fracture site. However, significant difference in outcome were noticed from open reduction and internal fixation in comparison to closed reduction and percutaneous pinning. 5. In all 39 cases, lateral condylar overgrowth (10 cases), cubitus varus (1 cases) and cubitus valgus (3 cases) were noticed as complications but clinical significance was not noted. 6. The above results suggest that internal fixation is recommended for firm fixation although displacement is not severe. In case of Jakob's stage III, anatomical reduction is required in order to reduce additional damage on articular surface and epiphyseal plate caused by excessive manipulation.
Child
;
Clinical Study
;
Follow-Up Studies
;
Growth Plate
;
Hospitals, General
;
Humans
;
Humerus
;
Incidence
;
Methods
4.Massive Pneumoperitoneum After Scuba Diving.
Seung Tak OH ; Wook KIM ; Hae Myung JEON ; Jeong Soo KIM ; Kee Whan KIM ; Seung Jin YOO ; Eung Kuk KIM
Journal of Korean Medical Science 2003;18(2):281-283
Pneumoperitoneum usually indicates rupture of a hollow viscus and considered a surgical emergency. But air may also enter the peritoneum from the lung or the genital organs in female without visceral perforation. While scuba diving, the rapid ascent is usually controlled by placing in a decompression chamber and the excess gas volume is exhaled. Failure to allow this excess gas to escape will result in overdistension of air passage, which may rupture resulting in pulmonary interstitial emphysema or, if air enters the circulation, air embolus can occur. Pneumo-peritoneum is a rare complication of diving accidents. While the majority of cases are not related to an intraabdominal catastrophy, more than 20% have been the result of gastric rupture. We report a 42-yr-old male patient with massive pneumoperitoneum after scuba diving, who presented himself with dyspnea and abdominal distension. Knowledge of this rare condition and its benign course may allow the emergency physician and surgeon to order appropriate studies to help avoid unnecessary surgical treatment. It is important to determine promptly whether the air emanated from a ruptured viscus or was introduced from an extraperitoneal source. Free air in the abdomen does not always indicate a ruptured intra-abdominal viscus.
Adult
;
Diving/adverse effects*
;
Female
;
Human
;
Male
;
Pneumoperitoneum/diagnosis*
;
Pneumoperitoneum/etiology*
;
Radiography, Abdominal
;
Radiography, Thoracic
5.Usefulness of Anterior Cervical Interbody Fusion Using Locally Harvested Bone: Minimum 5-Year Follow-Up.
Dae Moo SHIM ; Tae Kyun KIM ; Sung Kyun OH ; Seung Whan KUK ; Bong Jun JANG ; Ji Woong CHOI
The Journal of the Korean Orthopaedic Association 2016;51(3):191-198
PURPOSE: The purpose of this study is to determine the usefulness of locally harvested autobone as a filling material for fusion. MATERIALS AND METHODS: Retrospective study was conducted for 21 patients diagnosed as cervical disc herniation with cervical myelopathy or radiculopathy who underwent anterior cervical fusion using locally harvested autobone and polyetheretherketone solis cage from June 2006 to September 2009, with a follow-up period of longer than 5 years. Radiologic outcomes were evaluated by the rate of bone union, the change of intervertebral height, and the subsidence of the cage. RESULTS: In clinical results, visual analogue scale score was 5.8±0.71/7.7±0.78 at preoperative, 1.6±0.58/2.3±0.97 at 1-year follow-up, 1.8±0.81/2.7±1.28 at 5-year follow-up, and neck disability index score was 34.3±6.2 in preoperative stage, 6.25±3.21 at 1-year follow-up, and 6.51±4.05 at 5-year follow-up. Radiologically intervertebral height was reduced from average 6.31±0.93 mm in 1-year follow-up to average 6.22±0.85 mm in 5-year follow-up. Subsidence of cage was average 1.28±0.41 mm at 1-year follow-up and average 1.31±0.43 mm at 5-year follow-up, with no statistically significant difference (p>0.05). Average subsidence of cage in these cases was 3.25 mm. In postoperative complication, screw breakage occurred in 1 case, screw pull out occurred in 1 case, and there was no postoperative infection. CONCLUSION: Using locally harvested autobone as filling material for fusion resulted in outstanding bone union and improvement of clinical results. In long term follow-up, there was no significant difference in union rate and complication incidence. Therefore use of locally harvested autobone as a filling material for fusion is considered an effective method.
Follow-Up Studies*
;
Humans
;
Incidence
;
Methods
;
Neck
;
Postoperative Complications
;
Radiculopathy
;
Retrospective Studies
;
Spinal Cord Diseases
6.Pre-hospital delay and emergency medical services in acute myocardial infarction
Seung Hun LEE ; Hyun Kuk KIM ; Myung Ho JEONG ; Joo Myung LEE ; Hyeon-Cheol GWON ; Shung Chull CHAE ; In-Whan SEONG ; Jong-Seon PARK ; Jei Keon CHAE ; Seung-Ho HUR ; Kwang Soo CHA ; Hyo-Soo KIM ; Ki-Bae SEUNG ; Seung-Woon RHA ; Tae Hoon AHN ; Chong-Jin KIM ; Jin-Yong HWANG ; Dong-Ju CHOI ; Junghan YOON ; Seung-Jae JOO ; Kyung-Kuk HWANG ; Doo-Il KIM ; Seok Kyu OH ;
The Korean Journal of Internal Medicine 2020;35(1):119-132
Background/Aims:
Minimising total ischemic time (TIT) is important for improving clinical outcomes in patients with ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention (PCI). TIT has not shown a significant improvement due to persistent pre-hospital delay. This study aimed to investigate the risk factors associated with pre-hospital delay.
Methods:
Individuals enrolled in the Korea Acute Myocardial Infarction Registry-National Institutes of Health between 2011 and 2015 were included in this study. The study population was analyzed according to the symptom-to-door time (STDT; within 60 or > 60 minutes), and according to the type of hospital visit (emergency medical services [EMS], non-PCI center, or PCI center).
Results:
A total of 4,874 patients were included in the analysis, of whom 28.4% arrived at the hospital within 60 minutes of symptom-onset. Old age (> 65 years), female gender, and renewed ischemia were independent predictors of delayed STDT. Utilising EMS was the only factor shown to reduce STDT within 60 minutes, even when cardiogenic shock was evident. The overall frequency of EMS utilisation was low (21.7%). Female gender was associated with not utilising EMS, whereas cardiogenic shock, previous myocardial infarction, familial history of ischemic heart disease, and off-hour visits were associated with utilising EMS.
Conclusions
Factors associated with delayed STDT and not utilising EMS could be targets for preventive intervention to improve STDT and TIT.
7.Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study
Min KIM ; Kyoung Hwa HA ; Junyoung LEE ; Sangshin PARK ; Kyeong Seok OH ; Dae-Hwan BAE ; Ju Hee LEE ; Sang Min KIM ; Woong Gil CHOI ; Kyung-Kuk HWANG ; Dong-Woon KIM ; Myeong-Chan CHO ; Dae Jung KIM ; Jang-Whan BAE
Korean Circulation Journal 2024;54(5):256-267
Background and Objectives:
Accumulating evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce adverse cardiovascular outcomes. However, whether SGLT2i, compared with other antidiabetic drugs, reduce the new development of atrial fibrillation (AF) is unclear. In this study, we compared SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4is) in terms of reduction in the risk of AF in individuals with type 2 diabetes.
Methods:
We included 42,786 propensity score-matched pairs of SGLT2i and DPP-4i users without previous AF diagnosis using the Korean National Health Insurance Service database between May 1, 2016, and December 31, 2018.
Results:
During a median follow-up of 1.3 years, SGLT2i users had a lower incidence of AF than DPP-4i users (1.95 vs. 2.65 per 1,000 person-years; hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.55–0.97; p=0.028]). In individuals without heart failure, SGLT2i users was associated with a decreased risk of AF incidence (HR, 0.70; 95% CI, 0.52–0.94; p=0.019) compared to DPP-4i users. However, individuals with heart failure, SGLT2i users was not significantly associated with a change in risk (HR, 1.04; 95% CI, 0.44–2.44; p=0.936).
Conclusions
In this nationwide cohort study of individuals with type 2 diabetes, treatment with SGLT2i was associated with a lower risk of AF compared with treatment with DPP-4i.
8.Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study
Min KIM ; Kyoung Hwa HA ; Junyoung LEE ; Sangshin PARK ; Kyeong Seok OH ; Dae-Hwan BAE ; Ju Hee LEE ; Sang Min KIM ; Woong Gil CHOI ; Kyung-Kuk HWANG ; Dong-Woon KIM ; Myeong-Chan CHO ; Dae Jung KIM ; Jang-Whan BAE
Korean Circulation Journal 2024;54(5):256-267
Background and Objectives:
Accumulating evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce adverse cardiovascular outcomes. However, whether SGLT2i, compared with other antidiabetic drugs, reduce the new development of atrial fibrillation (AF) is unclear. In this study, we compared SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4is) in terms of reduction in the risk of AF in individuals with type 2 diabetes.
Methods:
We included 42,786 propensity score-matched pairs of SGLT2i and DPP-4i users without previous AF diagnosis using the Korean National Health Insurance Service database between May 1, 2016, and December 31, 2018.
Results:
During a median follow-up of 1.3 years, SGLT2i users had a lower incidence of AF than DPP-4i users (1.95 vs. 2.65 per 1,000 person-years; hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.55–0.97; p=0.028]). In individuals without heart failure, SGLT2i users was associated with a decreased risk of AF incidence (HR, 0.70; 95% CI, 0.52–0.94; p=0.019) compared to DPP-4i users. However, individuals with heart failure, SGLT2i users was not significantly associated with a change in risk (HR, 1.04; 95% CI, 0.44–2.44; p=0.936).
Conclusions
In this nationwide cohort study of individuals with type 2 diabetes, treatment with SGLT2i was associated with a lower risk of AF compared with treatment with DPP-4i.
9.Lower Atrial Fibrillation Risk With Sodium-Glucose Cotransporter 2Inhibitors Than With Dipeptidyl Peptidase-4 Inhibitors in Individuals With Type 2 Diabetes: A Nationwide Cohort Study
Min KIM ; Kyoung Hwa HA ; Junyoung LEE ; Sangshin PARK ; Kyeong Seok OH ; Dae-Hwan BAE ; Ju Hee LEE ; Sang Min KIM ; Woong Gil CHOI ; Kyung-Kuk HWANG ; Dong-Woon KIM ; Myeong-Chan CHO ; Dae Jung KIM ; Jang-Whan BAE
Korean Circulation Journal 2024;54(5):256-267
Background and Objectives:
Accumulating evidence shows that sodium-glucose cotransporter 2 inhibitors (SGLT2is) reduce adverse cardiovascular outcomes. However, whether SGLT2i, compared with other antidiabetic drugs, reduce the new development of atrial fibrillation (AF) is unclear. In this study, we compared SGLT2i with dipeptidyl peptidase-4 inhibitors (DPP-4is) in terms of reduction in the risk of AF in individuals with type 2 diabetes.
Methods:
We included 42,786 propensity score-matched pairs of SGLT2i and DPP-4i users without previous AF diagnosis using the Korean National Health Insurance Service database between May 1, 2016, and December 31, 2018.
Results:
During a median follow-up of 1.3 years, SGLT2i users had a lower incidence of AF than DPP-4i users (1.95 vs. 2.65 per 1,000 person-years; hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.55–0.97; p=0.028]). In individuals without heart failure, SGLT2i users was associated with a decreased risk of AF incidence (HR, 0.70; 95% CI, 0.52–0.94; p=0.019) compared to DPP-4i users. However, individuals with heart failure, SGLT2i users was not significantly associated with a change in risk (HR, 1.04; 95% CI, 0.44–2.44; p=0.936).
Conclusions
In this nationwide cohort study of individuals with type 2 diabetes, treatment with SGLT2i was associated with a lower risk of AF compared with treatment with DPP-4i.
10.Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study)
Keun Ho PARK ; Myung Ho JEONG ; Young Joon HONG ; Youngkeun AHN ; Hyun Kuk KIM ; Young Yub KOH ; Doo Il KIM ; Sang Wook KIM ; Weon KIM ; Seung Woon RHA ; Jay Young RHEW ; Jong Seon PARK ; Hun Sik PARK ; Jang Ho BAE ; Jang Whan BAE ; Seok Kyu OH ; Sung Yun LEE ; Seung Wook LEE ; Jae Hwan LEE ; Sang Yeob LIM ; Jang Hyun CHO ; Kwang Soo CHA ; Jai Keon CHAE ; Seung Ho HUR ; Sun Ho HWANG ; Jin Yong HWANG
Yonsei Medical Journal 2018;59(1):72-79
PURPOSE: This study sought to determine the 1-year clinical effectiveness and safety of a biodegradable, polymer-containing Biolimus A9™-eluting stent (BES) in Korean patients with acute coronary syndrome (ACS). MATERIALS AND METHODS: A total of 1000 ACS patients with 1251 lesions who underwent implantation of BESs at 22 centers in Korea were enrolled between May 2011 and July 2013. We assessed major adverse cardiac events (MACE) defined as the composite of cardiac death, non-fatal myocardial infarction (MI), and clinical-driven target vessel revascularization at 12 months. RESULTS: Patient mean age was 62.6±11.4 years. 72.8% of the patients were male, 28.5% had diabetes, 32.8% had multi-vessel disease (MVD), and 47.9% presented with acute MI (AMI). The mean global registry of acute coronary events risk score of all patients was 103.0±27.6. The number of stents per patient was 1.3±0.6. The incidences of MACE and definite stent thrombosis at 12 months were 3.9% and 0.2%, respectively. On multivariate Cox-regression analysis, age ≥65 years was identified as an independent predictors of 1-year MACE (hazard ratio=2.474; 95% confidence interval=1.202−5.091). Subgroup analyses revealed no significant differences in the incidence of MACE between patients with and without diabetes (4.3% vs. 3.7%, p=0.667), between those who presented with and without AMI (4.4% vs. 3.4%, p=0.403), and between those with and without MVD (4.6% vs. 3.5%, p=0.387). CONCLUSION: Our study demonstrated excellent 1-year clinical outcomes of BES implantation in patients at low-risk for ACS.
Acute Coronary Syndrome/drug therapy
;
Aged
;
Drug-Eluting Stents/adverse effects
;
Female
;
Humans
;
Incidence
;
Kaplan-Meier Estimate
;
Male
;
Middle Aged
;
Multivariate Analysis
;
Proportional Hazards Models
;
Republic of Korea
;
Sirolimus/adverse effects
;
Sirolimus/analogs & derivatives
;
Sirolimus/therapeutic use
;
Time Factors
;
Treatment Outcome